arrow
M

Mona Bafadhel

king's collegelondon
H指数:48
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Reframing disease elimination: an update from the Lancet Commission on chronic obstructive pulmonary disease

重新定义疾病消除:来自《柳叶刀》慢性阻塞性肺疾病委员会的最新进展

2026-11-100
OA
Effect of budesonide/glycopyrronium/formoterol fumarate dihydrate on cardiopulmonary outcomes in COPD: rationale and design of the THARROS trial

布地奈德/格隆溴铵/富马酸福莫特罗二水合物对COPD患者心肺结局的影响: THARROS试验的原理和设计

2025-12-221
PRE
Blood Eosinophil Counts in Healthy Volunteers and in Patients with Asthma and COPD in India: A Multi-Centre Cross-Sectional Report

印度健康志愿者及哮喘与COPD患者中的血嗜酸性粒细胞计数:一项多中心横断面报告

2025-12-010
OAAI
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial

II型炎症生物标志物及其与COPD患者对度普利单抗反应的相关性(BOREAS):一项随机、安慰剂对照III期试验的分析

2025-07-090
OAAI
The Risk–Benefit Balance of Oral Corticosteroid Treatment for Asthma Attacks: A Discrete Choice Experiment of Patients and Healthcare Professionals in the UK and New Zealand

哮喘急性发作口服皮质类固醇治疗的风险-获益平衡:英国和新西兰患者及医疗保健专业人员离散选择实验

2025-06-300
OAAI
Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores
2025-05-010
OA
Effect of Dupilumab on Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation

Dupilumab对具有COPD和2型炎症患者的健康相关生活质量及呼吸道症状的影响

CHEST
IF8.6
2025-01-310
OAAI